周一,百济神州(ONC.US)涨逾3%,报255.81美元。消息面上,百济神州6月23日宣布双特异性HER2抑制剂百赫安(注射用泽尼达妥单抗)在中国正式供应,并同步在全国多家医疗机构投入临床使用。作为中国首个且目前唯一1获批用于靶向治疗HER2高表达胆道癌的双特异性抗体,首批药物将迅速在全国百余个城市的医院和药房落地,惠及胆道癌(BTC)患者。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.